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Abstract: Tie-2, a kind of endothelial cell tyrosine kinase receptor, is required for 
embryonic blood vessel development and tumor angiogenesis. Several compounds that 
showed potent activity toward this attractive anticancer drug target in the assay have been 
reported. In order to investigate the structure-activity correlation of indolocarbazole series 
compounds and modify them to improve their selectivity and activity, 3D-QSAR models 
were built using CoMFA and CoMSIA methods and molecular docking was used to check 
the results. Based on the common sketch align, two good QSAR models with high 
predictabilities (CoMFA model: q
2 = 0.823, r
2 = 0.979; CoMSIA model: q
2 = 0.804,   
r
2 = 0.967) were obtained and the contour maps obtained from both models were applied to 
identify the influence on the biological activity. Molecular docking was then used to 
confirm the results. Combined with the molecular docking results, the detail binding mode 
between the ligands and Tie-2 was elucidated, which enabled us to interpret the   
structure-activity relationship. These satisfactory results not only offered help to 
comprehend the action mechanism of indolocarbazole series compounds, but also provide 
new information for the design of new potent inhibitors. 
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1. Introduction 
Tie-2, a kind of endothelial cell tyrosine kinase receptor, is expressed primarily by vascular endothelial 
cells and is required for embryonic blood vessel development and tumor angiogenesis [1]. Angiopoietin 
integrates with Tie-2 in the body to promote the Tie-2 receptor’s autophosphorylation, while the 
endothelial cells which express Tie-2 attract the cells around the vein to help the endothelial cells 
construct complete vessel walls, promote vascular remodeling and maturing, maintain the integrity of 
blood vessels and regulate their functions [2]. More and more data suggest that the inhibition of   
Tie-2 plays a vital part in curing cancer, and Tie-2 represents an important candidate for targeted 
therapy in cancer [3–5]. 
Recently, a novel series of indolocarbazole was reported as a kind of receptor tyrosine kinase 
inhibitor targeted to Tie-2 [6–9]. However, the QSAR focuses on indolocarbazole series compounds as 
Tie-2 inhibitors have not been reported. In our study, the 3D-QSAR models are constructed by   
CoMFA and CoMSIA methods on a training set of 80 indolocarbazole compounds as Tie-2 inhibitors. 
Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices 
Analysis (CoMSIA) are two commonly used three-dimensional quantitative structure–activity 
relationship (3D-QSAR) methods. It is a useful technique for understanding the pharmacological 
properties of studied compounds, because not only are the models visualized, but also the   
relationships between physical/chemical properties and pharmacological activity are represented in 
contour maps [10,11]. Combining with the docking study, the protein-ligand interactions were 
implicated. The models can help us to predict the biological activities of the series compounds with a 
change in the chemical substitutions and to provide some useful references for the design of new   
Tie-2 inhibitors. The theoretical results can offer some useful references for the design of new Tie-2 
inhibitors as anticancer drugs.  
2. Computational Methods 
2.1. Data Set and Molecular Sketching  
Except for some compounds with no activity or unclear activity, 80 indolocarbazole compounds 
from 4 references [6–9] are selected as the training set, among which 15 compounds are randomly 
chosen as the testing set (the testing set is marked by *). According to research practice, all original 
IC50 values (nmol/L) were converted to negative logarithm of IC50 (pIC50) and used as dependent 
variable in our 3D-QSAR study. The structure of these compounds and their activity values are listed 
in Table 1. 
Among all the compounds in the data set, compound 27 was selected as template to construct other 
compounds because of its highest biological activity, and the computation is completed by SYBYL7.3 
program package (Tripos. Int.) on a personal computer. Except for some special notes, default values 
are chosen to finish this work. The calculation can be defined as follows: after the construction of 
molecules, hydrogen and Gasteiger-Hückel charges were added to the compounds. Then their 
geometries are optimized by the conjugate gradient method in TRIPOS force field. The energy 
convergence criterion is 0.001 kcal/mol. Int. J. Mol. Sci. 2011, 12 
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Table 1. Molecular structures of training and test set and their inhibitory activities (pIC50).  
 
                                        1–17                                  18–75                            76–80 
NO R1 R 2 R 3 pIC50(nM) 
1 H  Me  H 6.83 
2 H  Et  H 6.58 
3   Me  Me  H  7.15 
4  i-Pr Me  H 6.58 
5  i-Pr Et  H  7.04 
6 Me  i-Pr H  7.55 
7 Me  Me  Pr 7.52 
8 Me  Me  i-Pr 7.01 
9 Me  Me i-Bu 7.52 
10 Me  Me  n-Bu 6.97 
11 Me  Et    i-Bu 7.60 
12 Me  i-Pr   i-Bu 7.28 
13 Me  i-Bu  i-Bu 7.64 
14   Me  Et   i-Pr 7.58 
15 Me  i-Pr  i-Pr 7.18 
16 Me  i-Bu   i-Pr 7.34 
17 Me  i-Bu   Et   7.35 
NO R1 R 2 pIC50(nM) 
18 NH2 CH2CH(CH3)2 7.32 
19 NH2 CH2CH2CH2CH3 6.64 
20 4-OMe–phenyl  NHCONH  CH2CH3 8.40 
21 4-OMe–phenyl  NHCONH  CH2CH2CH3 8.70 
22 4-OMe–phenyl  NHCONH  CH2CH(CH3)2 8.52 
23 4-OMe–phenylNHCONH  CH2CH2CH2CH3 8.15 
24 4-SMe–phenylNHCONH  CH2CH2CH3 8.52 
25 4-NMe2–phenylNHCONH  CH2CH2CH3 8.22 
26 4-Me–phenylNHCONH  CH2CH2CH3 8.52 
27 2-F-5-Me-phenylNHCONH CH2CH2CH3 9.00 
28 2-F-5-CF3-phenylNHCONH CH2CH2CH3 8.40 
29 PhenylNHCONH  CH2CH2CH3 8.30 
30 Phenyl(Me)NCONH  CH2CH2CH3 8.70 
31 3-OMe–phenylNHCONH  CH2CH(CH3)2 8.40 
32 2-OMe–phenylNHCONH  CH2CH(CH3)2 8.10 
33 4-F-phenylNHCONH CH2CH2CH3 8.70 
34 3-F-phenylNHCONH CH2CH2CH3 8.70 
35 2-F-phenylNHCONH CH2CH2CH3 8.70 
36 4-Cl-phenylNHCONH CH2CH2CH3 8.22 Int. J. Mol. Sci. 2011, 12 
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Table 1. Cont. 
NO  R1  R2 pIC50(nM)
37 2-Cl-phenylNHCONH CH2CH2CH3 8.52 
38 2-Br-phenylNHCONH CH2CH2CH3 8.40 
39 2-ThienylCONH  CH3 7.92 
40 2-ThienylCONH  CH2CH(CH3)2 8.00 
41 2-FuranylCONH  CH2CH2CH3 7.54 
42 2-FuranylCONH  CH2CH(CH3)2 7.70 
43 4-OMe–phenylOCONH  CH2CH2CH3 8.30 
44 4-F-phenylOCONH CH2CH2CH3 7.96 
45  i-PrOCONH CH2CH2CH3 7.96 
46 EtOCONH  CH2CH2CH3 7.74 
47 PrOCONH  CH2CH2CH3 8.15 
48 H  H  5.87 
49 H  nPr 6.87 
50 H  i-Bu 6.43 
51 Ac  i-Pr 6.14 
52 Ac  i-Bu 7.08 
53 2-Thiophene-CO  H  6.87 
54 2-Thiophene-CO  Et  7.37 
55 2-Thiophene-CO  Pr  7.59 
56 2-Thiophene-CO  i-Pr 7.62 
57 2-Thiophene-CO  i-Bu 7.70 
58 3-Thiophene-CO  i-Bu 7.20 
59 2-Furan-CO  i-Bu 7.14 
60 3-Cl-Thiophene-2-CO  CH2CH(CH3)2 7.89 
61 3-Br-Thiophene-2-CO  CH2CH(CH3)2 7.82 
62 3-Me-Thiophene-2-CO  CH2CH(CH3)2 8.30 
63 4-Me-Thiophene-2-CO  CH2CH(CH3)2 7.37 
64   3-Furan-CO  i-Bu 7.24 
65 
O  
H 7.36 
66  c-Pentyl 7.39 
67  c-Hexyl 6.99 
68 CH2CH2OEt 7.77 
69 (CH2)2OH 7.57 
70 (CH2)3OH 7.80 
71 Me  7.39 
72 Et  7.85 
73  i-Pr 8.00 
74  i-Pent 7.68 Int. J. Mol. Sci. 2011, 12 
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Table 1. Cont. 
NO  R1  R2  pIC50(nM) 
75 
 
n-Pent 7.11 
76 H  6.15 
77 Et  7.06 
78  i-Pr 6.99 
79  c-Pentyl 6.52 
80 (CH2)2OH 6.46 
Structural alignment is considered as one of the most sensitive parameters in CoMFA and CoMSIA 
study. In our work, the most active compound 27, was used as a template for alignment, and the 
common fragment of 65 compounds is shown in Figure 1(A). The compound 27 was used as the 
template for alignment, and the rest of compounds were aligned on it [12]. This process was performed 
by Database Align of SYBYL 7.3. The aligned molecules were presented in Figure 1(B). 
Figure 1. Superposition of compounds in the training and test sets using the common 
substructure-based alignment rules. (A) Common substructure-based alignment;   
(B) superposition of compounds in the training and test sets.  
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2.2. CoMFA and CoMSIA Study 
In the CoMFA procedure, a 3D cubic lattice with a grid spacing of 2Ǻ was created automatically by 
the program to encompass all the aligned ligands. A default sp
3-carbon probe atom with a van der 
Waals radius of 1.52 Ǻ and a charge of +1.0 was used to generate steric (Lennard-Jones 6–12 
potential) field energies and electrostatic (Coulombic potential) fields with a distance-dependent 
dielectric at each lattice point. The computed field energy was truncated to 30 kcal/mol for both steric 
and electrostatic fields [12,13]. 
The CoMSIA procedure is similar to the CoMFA procedure. In this approach, five different 
similarity fields are calculated: steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen 
bond acceptor. The CoMSIA similarity index descriptors were derived using the same lattice box as 
that used in CoMFA calculations. These fields were selected to cover the major contributions to ligand 
binding. In CoMSIA fields, singularities were avoided at atomic positions because a Gaussian type Int. J. Mol. Sci. 2011, 12 
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distance dependence of each physicochemical property was adopted and thus no arbitrary cutoffs were 
necessary [14]. The attenuation factor was set to the default value of 0.3. 
The Partial Least Squares (PLS) regression technique was used to construct a linear correlation 
between the 3D-field (independent variables) and the biological activity values (dependent variables).  
Cross-validations were performed by the leave-one-out (LOO) procedure to in which one compound 
was removed from the data set and its activity is predicted using a model built from the rest of data  
set [14,15]. It results in the cross-validation square correlation coefficient q
2 and the optimum number 
of components (ONC). Then the optimum number of components was employed to construct   
3D-QSAR models by non-cross-validations to obtain the conventional correlation coefficient r
2, 
standard deviation SE and significant factor F. In order to speed up the analysis and reduce the noise, 
the column filter value of 2.0kcal/mol was set for non-cross-validations. The analysis procedure was 
performed by combing the bioactivity values (pIC50) and the corresponding field descriptor variation.  
2.3. Predictive Correlation Co-efficient (r
2
pred) 
In order to assess the predictive abilities of the CoMFA and CoMSIA models, the pIC50 values of an 
external test set composed of fifteen compounds were predicted. Furthermore, the predictive 
correlation coefficient r
2
pred was calculated by the formula shown below.  
r
2
pred = (SD − PRESS)/SD 
where SD is the sum of the squared deviations between the biological activities of the test set 
compounds and the mean activity of the training set compounds, and PRESS is the sum of squared 
deviations between experimental and predicted activity values of the test set compounds [16,17]. 
2.4. Molecular Docking 
In order to determine the appropriate binding conformations of these compounds and check the 
main factors affecting the activity from the 3D-QSAR models, docking study for all compounds was 
performed with the Surflex-Dock program from Sybyl7.3. The Surflex-Dock uses an empirical scoring 
function and a patented search engine to dock ligands into a protein’s binding site [18]. The scoring 
function considers the four terms, including the hydrophobic complementarity, polar complementarity, 
entropic terms and solvation terms. Protomol, an idealized representation of a ligand that makes every 
potential interaction with the binding site, was used to guide molecular docking. In our study, the 
protomol was established guiding by the ligand in the protein. The X-ray crystal structure of Tie-2 was 
retrieved from the RCSB Protein Data Bank (PDB entry code: 3l8p). At the beginning of the docking, 
all the water and ligands were removed and the random hydrogen atoms were added. Then the receptor 
structure was minimized in 10,000 cycles with Powell method in sybyl7.3 [19]. The surface of protein 
was calculated with a MOLCAD program. Other parameters used in docking were default, except for 
those explained.  Int. J. Mol. Sci. 2011, 12 
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3. Results and Discussion 
3.1. 3D-QSAR Models  
Two QSAR models are established from CoMFA and CoMSIA analysis and the statistical 
parameters derived from the experiment are listed in Table 2. These parameters demonstrate that both 
QSAR models obtained are of high degree of confidence and strong predictive ability. The CoMFA 
model had a high cross-validated square correlation coefficient q
2 (0.823) with an optimized 
component of 8, which suggests that the model is reliable and predictive, for q
2 is greater than   
0.5 indicating a model with good predictability [18–20]. The non-cross-validated square correlation 
coefficient r
2 is 0.979(r
2 is closer to 1 indicates better linear relationship) with a low standard error 
estimate (SEE) of 0.114, and F value of 319.429. Contributions of steric and electrostatic fields were 
0.527 and 0.473, indicating that the steric interaction of the ligand with the receptor may be a more 
important influencing factor for the anticancer activity.  
Table 2. Results of CoMFA and CoMSIA Models. 
PLS Statistics  CoMFA  CoMSIA 
q
2 a 0.823  0.804 
r
2 b 0.979  0.967 
ONC 
c   8  8 
SEE 
d   0.114  0.141 
F value 
e 319.429  207.935 
r
2
pred 
f 0.948  0.935 
Field Contribution(%)     
Steric 0.527  0.121 
Electrostatic 0.473  0.236 
Hydrophobic –  0.160 
H-bond Donor  –  0.225 
H-bond Acceptor  –  0.259 
a cross-validated square correlation coefficient; 
b non-cross-validated square correlation coefficient; 
c optimal number of components; 
d standard error of estimate; 
e value F-test; 
f predictive   
correlation coefficient. 
Compared with the CoMFA model, the CoMSIA model is a bit poor, but it is also a good model 
with high predictability (q
2 value of 0.804 for eight components and a conventional r
2 value of 0.967 
with a SEE of 0.141, F value of 207.935, shown in Table 2). The r
2
Pred value of 0.935 also shows that 
the predictive ability of the model are good, as does the CoMFA model with the r
2
Pred value of 0.948. 
The contribution of five fields: steric, electrostatic, hydrophobic, hydrogen-bond donor and   
hydrogen-bond acceptor, were 0.121, 0.236, 0.160, 0.225, and 0.259, respectively. 
The actual and predicted pIC50 values of the training set and the test set by two models are listed in 
Table 3, and the linear relationship for the CoMFA and CoMSIA analysis are shown in Figure 2 (a is 
the CoMFA model and b is the CoMSIA model), in which most points are evenly distributed along the 
line Y = X. It can clearly be seen that the predicted pIC50 values obtained from CoMFA and CoMSIA 
models are in good agreement with the experimental data.  Int. J. Mol. Sci. 2011, 12 
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Table 3. The experimental pIC50 values(nM), predicted pIC50 value (Pred.) and their 
residuals (Res.) of the indolocarbazole derivatives training and the test set molecules 
(labeled by *). 
Compd. No.  Experimental  CoMFA  CoMSIA 
   Pred. Res. Pred. Res. 
1    6.830 6.604 0.226 6.606 0.224 
2   6.578  6.726  −0.148 6.679 −0.101 
3  7.149 6.961 0.188 6.953 0.196 
4 6.578  6.807  −0.229 6.921 −0.343 
5  7.036 6.958 0.078 6.973 0.063 
6  *  7.553 7.001 0.552 7.122 0.431 
7  7.523 7.490 0.033 7.467 0.056 
8 7.013  7.175  −0.162 7.157 −0.144 
9 7.523  7.679  −0.156 7.597 −0.074 
10 *  6.967  7.321  −0.354 7.366 −0.399 
11 7.602  7.615  −0.013 7.571  0.031 
12  7.284 7.243 0.041 7.258 0.026 
13  7.638 7.520 0.118 7.519 0.109 
14 *  7.585  7.615  −0.030 7.620 −0.035 
15 7.180  7.261  −0.081 7.254 −0.074 
16 7.337  7.345  −0.008 7.220  0.117 
17 7.347  7.376  −0.029 7.447 −0.100 
18 7.319  7.359  −0.040 7.370 −0.051 
19 *  6.638  7.410  −0.771 7.481 −0.842 
20  8.398 8.394 0.004 8.366 0.032 
21 8.699  8.774  −0.075 8.589  0.110 
22  8.523 8.496 0.027 8.415 0.108 
23 8.155  8.249  −0.094 8.249 −0.094 
24 8.523  8.537  −0.014 8.583 −0.060 
25 *  8.223  8.472  −0.251 8.613 −0.390 
26 8.523  8.628  −0.105 8.698 −0.175 
27  9.000 8.823 0.177 8.680 0.320 
28  8.398 8.351 0.047 8.475  −0.077 
29 8.301  8.416  −0.115 8.484 −0.183 
30  8.699 8.662 0.037 8.626 0.073 
31  *  8.398 8.286 0.112 8.338 0.060 
32 8.097  8.208  −0.111 8.059 −0.038 
33  8.699 8.659 0.040 8.701  −0.002 
34  8.699 8.694 0.005 8.707  −0.008 
35  8.699 8.668 0.031 8.771  −0.072 
36 *  8.223  8.596  −0.374 8.794 −0.572 
37  8.523 8.465 0.058 8.689  −0.166 Int. J. Mol. Sci. 2011, 12 
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Table 3. Cont. 
Compd. No.  Experimental  CoMFA  CoMSIA  Compd. No.  Experimental
   Pred. Res.    
38 8.398  8.406  −0.008 8.436 −0.038 
39 7.921  7.989  −0.068 7.925 −0.004 
40 *  8.000  8.537  −0.537 8.121 −0.121 
41 7.538  7.665  −0.127 7.664 −0.126 
42  7.699 7.545 0.154 7.587 0.112 
43  8.301 8.243 0.058 8.136 0.165 
44 7.959  8.027  −0.068 8.014 −0.005 
45 7.959  7.960  −0.001 7.878  0.081 
46 7.745  7.758  −0.014 7.839 −0.094 
47  8.155 8.063 0.092 7.919 0.236 
48 5.867  6.049  −0.182 5.975 −0.108 
49  *  6.867 6.571 0.296 6.557 0.310 
50  6.429 6.384 0.045 6.244 0.185 
51 6.139  6.177  −0.038 6.233 –0.094 
52 7.081  7.132  −0.051 6.968  0.113 
53  6.866 6.742 0.124 6.882  −0.016 
54  *  7.366 7.360 0.006 7.416  −0.050 
55 7.585  7.694  −0.109 7.669 −0.114 
56 7.620  7.625  −0.005 7.614  0.006 
57  7.699 7.572 0.127 7.694 0.005 
58  7.201 7.089 0.112 7.168 0.032 
59 *  7.143  7.219  −0.076 7.437 −0.294 
60  7.886 7.775 0.111 7.755 0.131 
61  *  7.824 7.782 0.042 7.834  −0.010 
62 8.301  8.397  −0.096 8.293  0.008 
63 7.366  7.428  −0.062 7.559 −0.193 
64  7.237 7.111 0.126 7.139 0.098 
65  7.356 7.330 0.026 7.354 0.002 
66 7.387  7.557  −0.170 7.634 −0.267 
67  6.991 6.971 0.002 7.037  −0.044 
68  7.770 7.719 0.051 7.671 0.099 
69 *  7.569  7.574  −0.005 7.577 −0.009 
70  7.796 7.738 0.058 7.741 0.055 
71 *  7.387  7.639  −0.252 7.966 −0.579 
72 7.854  7.968  −0.114 8.049 −0.195 
73  8.000 7.821 0.179 7.650 0.350 
74  *  7.678 7.247 0.431 7.343 0.335 
75  7.108 7.077 0.031 7.179  −0.071 
76 6.146  6.219  −0.073 6.305 −0.159 
77  7.056 6.794 0.262 6.926 0.130 
78  6.987 6.979 0.008 7.032  −0.045 
79  6.522 6.456 0.066 6.485 0.037 
80 6.456  6.652  −0.196 6.484  0.028 Int. J. Mol. Sci. 2011, 12 
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Figure 2. Graph of actual versus predicted pIC50 values of the training set and the test set 
molecular using the CoMFA model (A) and CoMSIA model (B).  
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3.2. Contour Analysis 
The contour maps were used to display the fields around the molecules, and to rationalize where 
changes in each field probably affect the activity of the molecule. The models from CoMFA and 
CoMSIA were graphically interpreted through the stdev*coeff contour maps, which are plotted as the 
percentages of the contribution of CoMFA or CoMSIA equation. They show regions where variations 
of steric, electrostatic, hydrophilic, hydrogen-bond donor or acceptor nature in the structural features 
of the different molecules lead to an increase or decrease in the activity [20–22]. 
The contour maps of CoMFA are displayed in Figure 3. The steric field (A) is characterized by 
green and yellow contours, in which green indicates that increased steric is associated with enhanced 
activity and yellow indicated reduced activity. Compound 16 was selected as a reference molecule. Int. J. Mol. Sci. 2011, 12 
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There are green contours bellow the N-13 position, which suggested the suitable volume of alkyl at 
this position would increase the activity. The length of C3-C4 of N-alkyl substitution is probably 
suitable for improving the activity, shorter or longer lengths would decrease the activity. A bigger 
yellow contour beside the C-3 position and N-10 position shows that the more bulky substitutes in 
these areas will significantly decrease the biological activities. So, compared with the N-10 position 
alkynes substitutes (compound 77 and 78), the compounds with the methyl in the N-9 position (such as 
compounds 72 and 73) have bigger pIC50 values. Compound 16 has more potential than 15 because the 
i-tu is more bulky than i-Pr in the yellow area. This is satisfactory in accordance with the contour maps. 
The steric field (B) is characterized by blue and red contours, which indicates that the positive-charge 
groups and negative-charge groups would be favorable to the activity, respectively. As an   
electron-donating group, the isopropyl can decrease the positive-charge of the blue areas and decrease 
the activity, so compound 6 has the largest pIC50 value compared with compounds 1, 3 and 5. For 
another example, because the NHCO group is in the blue area, most of the compounds with phenyl 
urea have potential activity.  
Figure 3. CoMFA Std*coeff contour maps illustrating steric, electrostatic field. Compound 
16 was embedded in the map (A) while compound 5 was embedded in map (B). (A) Steric 
fields: green contours (90% contribution) indicate regions where bulky groups increase 
activity, while yellow contours (10% contribution) indicate regions where bulky groups 
decrease activity, and (B) Electrostatic fields: blue contours (90% contribution) indicate 
regions where electron-donating groups increase activity, while red contours (10% 
contribution) indicate regions where electron-withdrawing groups increase activity. 
(A) (B) 
Compared with the CoMFA model, the CoMSIA model provides more information. The CoMSIA 
contour maps involve three parts: the electrostatic and steric field contours, the hydrophobic field 
contours, and the hydrogen-bond donor and hydrogen-bond acceptor field contours. The CoMSIA 
steric and electrostatic contour plots shown in Figure 4(A,B) are consistent to those of CoMFA. The 
big or small ramificate alkyl substituent of N-13 position would decrease the activity. The CoMSIA 
hydrophobic contour plot is shown in Figure 4E using compound 72. The yellow regions indicate 
hydrophobic substitutions will increase the activity of the compounds, while the white areas show that 
hydrophilic substitutions will increase activity. The compounds with NHCO groups at C-3 position 
have potential activity probably because the NHCO groups as a hydrophilic in the white area. If the Int. J. Mol. Sci. 2011, 12 
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NHCO group was replaced by C=O such as the compound-58 analogues, they also shows the activity. 
However if the NHCO group was replaced by C=N-O groups such as the compounds-1-4 analogues, 
the activities would be decreased because of the C=N in white area with less hydrophilic.  
Figure 4. Std* coeff contour maps of CoMSIA illustrating steric, electrostatic, 
hydrophobic, hydrogen-bond donor and acceptor fields. Compound 16 was embedded in 
the map (A) while compound 4 was embedded in map (B). (A) Steric contour map: green 
contours refer to sterically favored regions while yellow contours refer to sterically 
disfavored regions. (B) Electrostatic contour map: blue contours refer to regions where 
electron-donating groups are favored while red contours indicate regions where   
electron-withdrawing groups are favored. (C) Hydrogen-bond donor contour map. The 
cyan (80% contribution) and the purple (20% contribution) contours indicate regions with 
favorable and unfavorable hydrogen-bond donor groups. (D) Hydrogen-bond acceptor 
contour map. The magenta contours (80% contribution) for hydrogen-bond acceptor groups 
increase activity; red contours (20% contribution) indicate the disfavored region.   
(E) Hydrophobic contour map. Yellow contours (85% contribution) indicate regions where 
hydrophobic substituents are favored, white contours (15% contribution) refer to regions 
where hydrophilic substituents are favored.  
 
(A) (B) (C) 
 
 
(D) (E)  
The hydrogen-bond donor and hydrogen-bond acceptor contour plots are shown in Figure 4 (C,D) 
using the compound 27. The blue regions highlight the hydrogen-bond donor’s contribution to the 
activity. The purple areas show the hydrogen-bond donor’s disadvantage in contributing to the activity. 
The hydrogen of the group NHCONH acted as hydrogen-bond donor would benefit the activity, 
however, if the hydrogen at the N-13 position is not replaced by alkyl, it would act as   
a hydrogen-bond donor in the purple areas, which can decrease the activity. This may explain why the 
compounds without N-alkylation at N-13 position have low pIC50 value. In the hydrogen-bond 
acceptor contour plot (Figure 4D), the red-purple and red regions represent those areas of favorable 
and unfavorable hydrogen-bond acceptor respectively. The C=O in the red regions shows it would Int. J. Mol. Sci. 2011, 12 
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decrease the activity. When the conformation was changed because of the substitution of phenyl (the 
C=O lie in the red-purple area), it could increase the activity, such as compounds 34 and 39.  
3.3. Docking Analysis 
In order to investigate the probable binding conformations between these indolocarbazole 
derivatives and the receptor, and to check the reliability of the established 3D-QSAR models, all 
studied inhibitors were docked into the active pocket of Tie-2. The crystal structure of Tie-2 was 
retrieved from the RCSB Protein Data Bank (PDB entry code: 3l8p). In order to validate the docking 
reliability, the ligand was removed from the active site and docked back into the binding pocket. The 
root mean square deviation (RMSD) between the predicted conformation and the actual conformation 
from the crystal structure of ligand was 0.609 Ǻ, which is smaller than the resolution of X-ray 
crystallography, 2.40 Ǻ. The results indicated that the parameter set for the Surflex-dock simulation 
was reasonable to reproduce the X-ray structure. Therefore the simulation method and the parameter 
set could be extended to study the binding conformations of the other inhibitors. 
After all molecules were aligned according the method mentioned above, we found most of the 
molecules adopted a similar binding conformation to the potent inhibitor and had same orientation 
with each other. However, some inhibitor with low activity exhibited different poses and influenced 
the alignment based on docking, such as compound 19, 48, etc. The high quality 3D-QSAR models 
based on docking alignment could, unfortunately, not be constructed. A docking study showed that if 
the group of C-3 position is not enough to match to the sub-hydrophobic pocket composed of Asn887, 
Leu888, Leu876, Leu985, Asp982, Phe983, the molecule might be have much more orientation 
because of the large binding pocket of Tie-2. Most compounds had the same interaction with Tie-2, 
especially those with high activity, we still could acquire enough information to demonstrate our   
3D-QSAR models. The following statements are the results of our docking studies, which are the 
complement of 3D-QSAR studies for drug design.  
The compounds 27 and 73 were selected for further detailed analysis. The best possible interacting 
model of compound 73 with Tie-2 and the main residues involved in the interaction were generally 
depicted in Figure 5. The O of C=O at C-7 position acted as a hydrogen-bond acceptor and formed a  
H-bond with the –NH of the Ala905 residue similarly to the hydrogen bond formed by O from epoxy 
cyclohexyl and the –NH of Asp982. The hydrogen of N-6 position served as the hydrogen donor by 
forming a H-bond with the C=O of the Glu903 residue. Docking study displayed almost compounds 
can form two hydrogen bonds: the O atom of C=O with H of –NH from Ala905 residue and the H of  
–NH with the O of C=O from Glu903. If the substitutes of C-3 position are not epoxy cyclohexane but 
urea dual or furan, the atom O generally acts as a hydrogen-bond acceptor and interacts with the amide 
acid of Tie-2. Int. J. Mol. Sci. 2011, 12 
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Figure 5. The binding mode between compound 73 and the Tie-2 acceptor (PDB: 3l8p). 
Key residues and hydrogen bonds are labeled. 
 
The knowledge of hydrogen-bonding sites on a molecular surface is a powerful tool for docking 
studies. Ligands can be docked to proteins by matching the patterns displayed on the surface. The 
surface is divided into three kinds of regions: hydrogen-bonding donating, hydrogen acceptor and the 
rest of the molecule. Figure 6 displayed the hydrogen bonding surface of active site of Tie-2 with in 
the compound 27. The observations obtained from Figure 6 are in agreement with that of CoMSIA 
hydrogen-bond donor and acceptor contour. 
Figure 6. The MOLCAD hydrogen-bonding surface of ATP pocket of Tie-2 within the 
compound 27. There are only three colors: red (hydrogen donor, low electronegativity), 
gray (no hydrogen donor or acceptor) and blue (hydrogen acceptor, high electronegativity).  
   
Figure 7 demonstrated the lipophilic potential surface (A) and electrostatic potential surface (B) of 
ATP-binding site of Tie-2 within compound 27. The methyl at N-9 position which is matched to the 
hydrophilic area is favorable to the activity. If the substitutes of 3-position is the flexible hydrophilic 
group which linked the hydrophobic phenyl substitutes, it will enhance the activity. The flexible bond 
may rotate to fit the hydrophobic pocket. Therefore the compounds-20-38 analogues have   
bigger pIC50 value. The conclusion from the lipophilic potential surface was satisfied according to  
the corresponding CoMSIA hydrophobic contour map. The compound 27 was docked into the   Int. J. Mol. Sci. 2011, 12 
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ATP–binding site, the red color shows the electron-withdrawing zone and purple color shows   
electron-donating zone. In Figure 7(B), the R3 position was found in a yellow area. 
Figure 7. The MOLCAD lipophilic potential surface (A) and electrostatic potential surface 
(B) of ATP-binding site of Tie-2 within compound 27. The color ramp for LP ranges from 
brown (highest lipophilic area of the surface) to blue (highest hydrophilic area). The color 
ramp for EP ranges from red (most positive) to purple (most negative). 
(A) (B) 
3.4. Design for New Inhibitors 
Based on the analysis of the structure-activity relationship and the docking studies, a series of novel 
compounds were designed as the active tie-2 inhibitor. These compounds were aligned to the database 
using compound 27 as a template and the theoretical pIC50 values were predicted by the CoMFA and 
CoMSIA models. They also were docked into the pocket of Tie-2. The chemical structure and the 
predicted pIC50 value so as to the dock score were shown in Table 4. The high predicted activity and 
the better dock score showed that they would be a potent inhibitor to Tie-2 in the future.  
Table 4. Chemical structure of newly designed compounds and their predicted pIC50 and 
the Surflex-dock total-scores. 
N
H
N
N
N
N
O
N
R
O
R1 R2
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Table 4. Cont. 
No. 
Substituent  Predicted pIC _50(nM) 
Total-Score 
R R1 R 2 CoMFA  CoMSIA 
D1 2-F-5-Me-phenyl  CH3 H 9.024  8.380 13.35 
D2 2-F-5-Me-phenyl CH2CH3 H  8.966  8.508  14.02 
D3 5-Me-phenyl  CH(CH3)2 H  8.906  8.519  11.88 
D4 2-F-5-Me-phenyl  CH(CH3)2 H  8.951  8.515  11.18 
D5 2-F-5-Me-phenyl  H  OH  8.953  8.896  11.54 
D6 2-F-5-Me-phenyl  OH  OH  8.971  8.588  11.43 
D7 2-F-5-Me-phenyl  OCH3 OH  8.947  8.572  11.31 
D8 2-F-5-Me-phenyl  OH  CH3 8.786  8.250  12.36 
D9 3-F-6-Me-2-pyridyl  H  H  8.769  8.655  9.69 
4. Conclusion 
In this study, the 3D-QSAR study and molecular docking were carried out not only to construct 
highly accurate and predictive 3D-QSAR models, including the CoMFA (q
2 = 0.823, r
2 = 0.979,   
SEE = 0.114) and CoMSIA (q
2 = 0.804, r
2 = 0.967, SEE = 0.141), but also to explore the interaction 
mechanism between the  indolocarbazole compounds and Tie-2. The results from the combined   
3D-QSAR and docking study are: (1) The length of alkyl chain of N-13 position up to C3-C4 is 
favorable to the anticancer activity as larger or smaller alky cannot match to the pocket   
of active site of Tie-2; (2) The C-3 position suggested hydrophobic flexible group linked with the 
hydrogen-donor substituent are favored to the binding, which fits to the hydrophobic pocket of active 
site. Moreover, the hydrogen-donor group may form the hydrogen bond with the residues from Tie-2 
through the rotation of flexible bonds. If the group is electron-negative at this position, the activity 
would be enhanced; (3) The methyl at N-9 position is more favorable than at N-10 position, because 
the bulky group in N-10 position may decrease the activity. The 6-position N-H and the 7-position 
C=O are requirements for the biological activity because of the hydrogen bonds and hydrophilic.The 
results from VEGFR2 did not conform to the regular, expected statistic for a kind of dual VEGFR2 
and Tie 2 inhibitor and unfortunately the 3D-QSAR models could not be obtained. We can modify the 
indolocarbazole structures which were potent to VEGFR2 in order to improve the activity to Tie-2 
based on the information from the QSAR models and docking and design new potent dual inhibitors to 
Tie-2 and VEGFR2. 
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